See more : Eicher Motors Limited (EICHERMOT.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Neurocrine Biosciences, Inc. (NBIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurocrine Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Patriot Battery Metals Inc. (PMET.V) Income Statement Analysis – Financial Results
- Anacortes Mining Corp. (XYZFF) Income Statement Analysis – Financial Results
- ASNOVA CO LTD (9223.T) Income Statement Analysis – Financial Results
- Corep Lighting Société anonyme (MLCOR.PA) Income Statement Analysis – Financial Results
- JS Global Lifestyle Company Limited (1691.HK) Income Statement Analysis – Financial Results
Neurocrine Biosciences, Inc. (NBIX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neurocrine.com
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M | 451.24M | 161.63M | 15.00M | 19.77M | 0.00 | 2.92M | 53.14M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 14.59M | 16.80M | 16.00M | 26.10M | 19.20M |
| Cost of Revenue | 39.70M | 23.20M | 14.30M | 10.10M | 7.40M | 4.89M | 1.25M | 35.90M | 33.80M | 14.40M | 13.80M | 11.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.20M | -2.10M | -1.70M | -1.30M | -1.00M |
| Gross Profit | 1.85B | 1.47B | 1.12B | 1.04B | 780.70M | 446.35M | 160.37M | -20.90M | -14.03M | -14.40M | -10.88M | 41.54M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 16.79M | 18.90M | 17.70M | 27.40M | 20.20M |
| Gross Profit Ratio | 97.90% | 98.44% | 98.74% | 99.03% | 99.06% | 98.92% | 99.22% | -139.33% | -70.97% | 0.00% | -372.76% | 78.17% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.07% | 112.50% | 110.63% | 104.98% | 105.21% |
| Research & Development | 565.00M | 463.80M | 328.10M | 275.00M | 200.00M | 160.52M | 121.83M | 94.29M | 81.49M | 46.43M | 39.25M | 37.16M | 30.95M | 31.15M | 35.81M | 55.29M | 81.99M | 97.68M | 106.63M | 115.07M | 177.27M | 108.94M | 74.27M | 40.23M | 29.20M | 21.80M | 19.90M | 12.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.54M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -82.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 887.60M | 752.70M | 583.30M | 433.30M | 354.10M | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.46M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Other Expenses | 143.90M | 0.00 | 105.30M | 164.50M | 154.27M | 0.00 | -20.00K | 13.00K | 11.00K | 18.00K | 16.00K | 14.00K | 42.23M | 73.29M | 70.99M | 15.74M | 94.00M | 90.96M | 97.44M | 87.91M | 80.57M | 96.58M | 0.00 | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| Operating Expenses | 1.60B | 1.22B | 911.40M | 708.30M | 554.10M | 409.46M | 291.73M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 52.39M | 38.80M | 30.10M | 26.90M | 17.30M |
| Cost & Expenses | 1.64B | 1.24B | 925.70M | 718.40M | 561.50M | 414.35M | 292.99M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 50.19M | 36.70M | 28.40M | 25.60M | 16.30M |
| Interest Income | 0.00 | 11.20M | 3.80M | 12.60M | 19.21M | 0.00 | 0.00 | 2.84M | 1.93M | 629.00K | 400.00K | 489.00K | 435.00K | 397.00K | 691.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.60M | 7.10M | 25.80M | 32.80M | 32.00M | 30.53M | 19.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.30M | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M | 2.40M | 1.50M | 1.01M | 827.00K | 671.00K | 657.00K | 694.00K | 1.44M | 3.18M | 7.61M | 9.40M | 10.57M | 10.09M | 7.08M | 3.69M | 3.10M | 2.65M | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| EBITDA | 358.00M | 264.60M | 218.70M | 336.10M | 226.60M | 56.40M | -120.62M | -139.59M | -87.92M | -63.58M | -49.01M | 2.11M | 34.62M | -13.72M | -47.86M | -73.98M | -193.97M | -102.75M | -14.98M | -45.25M | -55.10M | -100.52M | -41.23M | -33.40M | -17.80M | -10.70M | 1.80M | 3.90M |
| EBITDA Ratio | 18.97% | 16.73% | 18.33% | 31.31% | 28.75% | 8.18% | -81.29% | -1,024.27% | -503.13% | 0.00% | -1,824.25% | -3.98% | 39.32% | -36.67% | -1,501.32% | -1,650.74% | -8,891.99% | -261.89% | -12.09% | -52.97% | -52.62% | -558.23% | -101.02% | -236.15% | -107.14% | -20.63% | -11.88% | 2.60% |
| Operating Income | 250.90M | 249.00M | 196.90M | 318.90M | 219.15M | 36.90M | -131.36M | -147.37M | -94.20M | -64.41M | -49.68M | 1.45M | 33.92M | -13.72M | -53.67M | -87.30M | -212.24M | -113.32M | -25.07M | -52.33M | -58.79M | -103.62M | -43.88M | -35.60M | -19.90M | -12.40M | 500.00K | 2.90M |
| Operating Income Ratio | 13.30% | 16.73% | 17.37% | 30.49% | 27.81% | 8.18% | -81.27% | -982.48% | -476.51% | 0.00% | -1,701.88% | 2.72% | 43.82% | -40.96% | -1,817.47% | -2,196.18% | -17,340.03% | -288.82% | -20.24% | -61.44% | -42.27% | -574.20% | -106.40% | -244.04% | -118.45% | -77.50% | 1.92% | 15.10% |
| Total Other Income/Expenses | 81.20M | -35.10M | -1.10M | -56.30M | -25.80M | -15.05M | -11.18M | 6.28M | 5.27M | 3.87M | 3.59M | 3.58M | 3.65M | 5.75M | 2.63M | -1.32M | 4.94M | 6.11M | 2.88M | 6.64M | 28.69M | 9.08M | 7.09M | 7.10M | 200.00K | -7.40M | 4.80M | 3.20M |
| Income Before Tax | 332.10M | 213.90M | 101.40M | 106.70M | 46.50M | 21.84M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -88.61M | -88.61M | -207.30M | -107.21M | -22.19M | -45.69M | -30.10M | -94.54M | -36.79M | -28.51M | -19.70M | -19.80M | 5.30M | 6.10M |
| Income Before Tax Ratio | 17.60% | 14.37% | 8.95% | 10.20% | 5.90% | 4.84% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -3,000.78% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.65% | -21.64% | -523.89% | -89.21% | -195.41% | -117.26% | -123.75% | 20.31% | 31.77% |
| Income Tax Expense | 82.40M | 59.40M | 11.80M | -300.60M | 9.50M | 730.00K | 17.10M | -7.72M | -6.27M | -4.68M | -4.24M | -4.22M | -4.26M | 0.00 | 173.00K | 1.32M | -4.94M | 0.00 | 0.00 | 79.00K | 158.00K | -9.08M | 120.00K | 302.00K | -3.10M | 7.60M | 200.00K | 200.00K |
| Net Income | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -51.04M | -88.61M | -207.30M | -107.21M | -22.19M | -45.77M | -30.26M | -94.54M | -36.91M | -28.81M | -16.80M | -20.00M | 5.10M | 5.90M |
| Net Income Ratio | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | 4.68% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -1,728.34% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.74% | -21.75% | -523.89% | -89.50% | -197.48% | -100.00% | -125.00% | 19.54% | 30.73% |
| EPS | 2.56 | 1.61 | 0.95 | 4.37 | 0.40 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.68 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.60 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.30 | 0.39 |
| EPS Diluted | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.67 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.58 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.28 | 0.36 |
| Weighted Avg Shares Out | 97.70M | 95.80M | 94.60M | 93.10M | 91.63M | 95.40M | 87.99M | 86.56M | 84.50M | 74.58M | 66.80M | 65.62M | 55.18M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 36.76M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 17.00M | 15.13M |
| Weighted Avg Shares Out (Dil) | 101.00M | 98.90M | 97.90M | 97.80M | 95.73M | 95.40M | 88.09M | 86.71M | 84.50M | 74.58M | 66.99M | 66.95M | 56.35M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 37.99M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 18.21M | 16.39M |
Neurocrine Biosciences to Participate at Investor Conferences in December
The 7th Annual Evercore HealthCONx Conference on December 3 Citi's 2024 Global Healthcare Conference on December 4 SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief...
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slow growth big pharma multiples, not at multiples of a company...
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Data Support Positive Impact of INGREZZA in People With Huntington's Disease Chorea Findings Presented at the 2024 Annual Meeting of the Huntington Study Group SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data...
Neurocrine Biosciences to Participate at Investor Conferences in November
2024 UBS Global Healthcare Conference on November 12 Stifel 2024 Healthcare Conference on November 18 Jefferies London Healthcare Conference on November 19 SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming...
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA® (valbenazine)...
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA® (valbenazine) capsules treatment. This research, "Remission...
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief...
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO , Oct. 30,...
Source: https://incomestatements.info
Category: Stock Reports